Valcyte (valganciclovir) is a prescription antiviral medication. Proper dosage, strict precautions, and a healthy lifestyle are effective measures to ensure efficacy and safety.

Dosage and Administration of Valcyte

1. Dosage for Adults

(1) Valcyte tablets are the only formulation for adults and must be taken with food.

(2) Treatment of cytomegalovirus (CMV) retinitis: Induction phase: 900 mg (two 450 mg tablets) twice daily for 21 consecutive days. Maintenance phase: 900 mg once daily.

(3) Prevention of CMV disease after transplantation: For heart or kidney-pancreas transplant patients, 900 mg once daily, initiated within 10 days postoperatively and continued until day 100. For kidney transplant patients, 900 mg once daily, initiated within 10 days postoperatively and continued until day 200.

2. Dosage for Children

(1) Oral solution (50 mg/mL) is preferred for children; tablets may only be used when the calculated dose is between 405–495 mg.

(2) For specific dosage details, consult a physician.

Precautions for Valcyte Use

1. Must Be Taken With Food

(1) Food increases the bioavailability of ganciclovir by approximately 30%, especially high-fat meals.

(2) Taking the medication on an empty stomach significantly reduces serum drug concentrations and impairs efficacy.

2. Tablets Must Not Be Split or Crushed

(1) Valcyte has potential teratogenic and carcinogenic properties; splitting or crushing increases the risk of skin and mucosal exposure.

(2) In case of accidental contact with damaged tablets or solution, immediately wash the skin with soap and water or rinse the eyes with water.

3. Regular Monitoring of Blood Routine and Renal Function

(1) Complete blood cell count, platelets, and serum creatinine must be monitored frequently before and during treatment.

(2) Avoid use if neutrophils are below 500/μL, platelets below 25,000/μL, or hemoglobin below 8 g/dL.

(3) Dosage should be adjusted promptly in patients with renal impairment.

4. Avoid Concomitant Use With Specific Medications

Drugs contraindicated or used with caution include: imipenem-cilastatin (may induce seizures), cyclosporine/amphotericin B (increased nephrotoxicity), mycophenolate mofetil (increased hematological and renal toxicity), didanosine (elevated didanosine concentrations), and probenecid (elevated ganciclovir concentrations). Concomitant use with other myelosuppressive or nephrotoxic drugs requires careful assessment of benefits and risks.

5. Contraceptive Requirements for Reproductive-Age Individuals

(1) Women must use effective contraception during treatment and for at least 30 days after discontinuation.

(2) Men must use condoms during treatment and for at least 90 days after discontinuation.

(3) Pregnancy testing is required for reproductive-age women before treatment.

6. Breastfeeding and Driving

(1) Breastfeeding is not recommended during treatment.

(2) Valcyte may cause seizures, dizziness, and confusion, impairing the ability to drive or operate machinery; caution is advised.

Healthy Lifestyle for Patients Taking Valcyte

1. Maintain Adequate Hydration

(1) Sufficient water intake reduces the risk of nephrotoxicity, especially in elderly patients or those taking concomitant nephrotoxic drugs.

(2) Daily water intake of 1.5–2 L or more is recommended, subject to physician advice.

2. Balanced Nutrition and Infection Prevention

(1) Patients with CMV disease and transplant recipients have weakened immunity; prioritize high-quality protein (fish, eggs, lean meat) and vitamin-rich fruits and vegetables.

(2) Avoid raw or undercooked foods to reduce infection risk.

(3) In case of severe diarrhea or vomiting, replenish fluids and electrolytes promptly.

3. Regular Ophthalmic Examinations

(1) Patients with CMV retinitis should undergo fundus examinations every 4–6 weeks even if symptoms improve.

(2) Valcyte does not cure the disease; some patients may develop retinal detachment or disease progression during or after treatment.

4. Avoid Driving and High-Risk Activities

(1) Avoid driving, operating machinery, or working at heights if tremors, dizziness, seizures, or confusion occur during treatment.

(2) Symptoms are usually reversible after discontinuation, but individualized assessment is required.

5. Emotional and Sleep Management

(1) Insomnia, anxiety, and depression are common side effects.

(2) Maintain a regular schedule, avoid caffeine and alcohol, and seek psychological support or medical advice if needed.

(3) Moderate exercise (e.g., walking) helps alleviate fatigue and improve mood.

6. Strict Adherence to Prescribed Dosage; Do Not Adjust Medication Independently

(1) Valcyte dosage adjustments must be based on renal function and blood test results; patients must not reduce the dose or discontinue the drug independently due to side effects.

(2) Any adjustments should be made in consultation with a physician.